Aimed Alliance Presents Testimony Urging FDA Panel’s Approval of Novel Treatment
Today, Aimed Alliance presented testimony before a joint meeting of the U.S. Food and Drug…
Browsing: Federal
FDA Releases Much-Anticipated Guidelines on Biosimilar Naming
This week, the U.S. Food and Drug Administration (FDA) released its much-anticipated guidelines on the…
Aimed Alliance Signs on to 21st Century Cures Letter
Today, the National Health Council sent a letter signed by Aimed Alliance and 250 other…
FDA Releases Three Final Guidances on Biosimilars
The U.S. Food and Drug Administration (FDA) has issued three final guidances on biosimilars, which…
Aimed Alliance Participates in CBI’s Q&A
In preparation for CBI’s Abuse Deterrent Formulations Summit, at which Aimed Alliance’s Director of Public…
The National Institute of Health Has Big Plans for Precision Medicine
The push for precision medicine is gaining momentum with bipartisan support and $210 million in…
“I Am (Still) Essential” Coalition Applauds Proposed Changes to EHBs and Makes Suggestions To Increase Positive Patient Outcomes
Today, the “I Am (Still) Essential” coalition of patient groups sent a letter signed by…
Quinnipiac Health Law Journal Publishes Aimed Alliance Article on Biologics
Quinnipiac University School of Law recently released its most recent volume of the Health Law…